<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Juhlin CC</submitter><funding>Cancerfonden</funding><pagination>401-410</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC7665972</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>31(4)</volume><pubmed_abstract>Neuroendocrine neoplasms (NENs) have traditionally been identified via expression of proteins associated to the regulation of secretory vesicles and granules. We report the clinical usage of the "second-generation" proteins ISL LIM homeobox 1 (ISL1), INSM transcriptional repressor 1 (INSM1), and secretagogin (SECG) as immunohistochemical markers of neuroendocrine differentiation since their introduction in clinical routine and compare the results with the established proteins chromogranin A (CGA) and synaptophysin (SYP). In total, 161 tumors, including 139 NENs and 22 "non-NENs" (unrelated tumors with an initial suspicion of NEN), were informatively stained for ISL1, and subsets were also interrogated for INSM1 and/or SECG. Diffuse or focal positive immunoreactivity was noted for ISL1 in 9</pubmed_abstract><journal>Endocrine pathology</journal><pubmed_title>Clinical Routine Application of the Second-generation Neuroendocrine Markers ISL1, INSM1, and Secretagogin in Neuroendocrine Neoplasia: Staining Outcomes and Potential Clues for Determining Tumor Origin.</pubmed_title><pmcid>PMC7665972</pmcid><funding_grant_id>Junior Clinical Investigator Award</funding_grant_id><pubmed_authors>Juhlin CC</pubmed_authors><pubmed_authors>Hoog A</pubmed_authors><pubmed_authors>Zedenius J</pubmed_authors></additional><is_claimable>false</is_claimable><name>Clinical Routine Application of the Second-generation Neuroendocrine Markers ISL1, INSM1, and Secretagogin in Neuroendocrine Neoplasia: Staining Outcomes and Potential Clues for Determining Tumor Origin.</name><description>Neuroendocrine neoplasms (NENs) have traditionally been identified via expression of proteins associated to the regulation of secretory vesicles and granules. We report the clinical usage of the "second-generation" proteins ISL LIM homeobox 1 (ISL1), INSM transcriptional repressor 1 (INSM1), and secretagogin (SECG) as immunohistochemical markers of neuroendocrine differentiation since their introduction in clinical routine and compare the results with the established proteins chromogranin A (CGA) and synaptophysin (SYP). In total, 161 tumors, including 139 NENs and 22 "non-NENs" (unrelated tumors with an initial suspicion of NEN), were informatively stained for ISL1, and subsets were also interrogated for INSM1 and/or SECG. Diffuse or focal positive immunoreactivity was noted for ISL1 in 9</description><dates><release>2020-01-01T00:00:00Z</release><publication>2020 Dec</publication><modification>2025-04-05T08:45:05.495Z</modification><creation>2024-11-09T16:43:40.187Z</creation></dates><accession>S-EPMC7665972</accession><cross_references><pubmed>32813226</pubmed><doi>10.1007/s12022-020-09645-y</doi></cross_references></HashMap>